

| | | | | | |
|--|--|--|--|--|---|
| Annual Registration Fee | | | | | £150 |
| Sample Handling | | | | | <p style="text-align: center;">Providing over 100 genomic EQAs encompassing the sample and patient journey</p> |
| Technical - Next Generation Sequencing | | | | | |
| Preimplantation Genetic Testing (PGT) | | | | | |
| Prenatal testing | | | | | |
| Molecular Newborn screening | | | | | |
| Postnatal constitutional - including joint molecular/cytogenomics | | | | | |
| Molecular Genetic Disorders - including Pharmacogenetics | | | | | |
| Haematological Neoplasms | | | | | |
| Molecular Pathology | | | | | |
| Variant Classification | | | | | |
| Clinical Genetics | | | | | |

| Sample Handling | EQA Code | Analysis | Sample Type | Accreditation status | Fee (£) |
|--|------------|----------------|--------------|-----------------------|---------|
| DNA extraction from venous blood | 2021DNAB | Technical only | Blood | Accredited | 1100 |
| DNA extraction from formalin-fixed paraffin embedded (FFPE) tissue | 2021DNAFFP | Technical only | FFPE | Accredited | 430 |
| DNA extraction from fresh frozen (FF) tissue | 2021DNAFF | Technical only | Fresh tissue | Pending accreditation | 530 |
| DNA extraction from saliva | 2021DNAS | Technical only | Saliva | Pending accreditation | 530 |
| DNA quantification | 2021DNAQ | Technical only | DNA | Pending accreditation | 315 |

| Technical - Next Generation Sequencing | EQA Code | Analysis | Sample Type | Accreditation status | Fee (£) |
|--|--|----------------|-------------------------------|-----------------------|---------|
| NGS germline ² | 2021NGSG | Technical only | Genomic DNA | Pending accreditation | 600 |
| NGS somatic panel ² | 2021NGSSP | Technical only | Somatic DNA | Pending accreditation | 600 |
| NGS somatic WES/WGS ² | 2021NGSSW | Technical only | Matched tumour / germline DNA | Pending accreditation | 920 |
| NGS EQA Package | Enrol in NGS germline EQA or NGS somatic panel EQA and save 50% on enrolment in any Classification of variants EQA. | | | | |

| Preimplantation Genetic Testing (PGT) | EQA Code | Analysis | Sample Type | Accreditation status | Fee (£) |
|---|--------------------------------------|--|-------------|----------------------|---------|
| PGT for Aneuploidies | PGTA | Technical, Genotyping and Interpretation | DNA | Accredited | 380 |
| PGT for Blastomere FISH (Stage 1 and 2) | PGTBF | Analytical and Interpretation | Images | Accredited | 380 |
| PGT for Monogenic Disorders (Stage 1) | PGTM | Technical, Genotyping and Interpretation | DNA | Accredited | 125 |
| PGT for Monogenic Disorders (Stage 2) | PGTM | Technical, Genotyping and Interpretation | Cells | Accredited | 255 |
| PGT for Polar bodies | PGTPB | Technical, Genotyping and Interpretation | DNA | Accredited | 380 |
| PGT for Structural Rearrangements | PGTSR | Technical, Genotyping and Interpretation | DNA | Accredited | 380 |
| PGT EQA Package | Enrol in 3 EQAs and save £40. | | | | |

| Prenatal Testing | EQA Code | Analysis | Sample Type | Accreditation status | Fee (£) |
|---|-----------|--|-------------|-----------------------|---------|
| Maternal cell contamination (MCC) and fetal sexing | 2021PNMCC | Technical, Genotyping and Interpretation | DNA | Accredited | 380 |
| Non-invasive prenatal testing (NIPT) for common aneuploidies ² | 2021NIPTA | Technical, Genotyping and Interpretation | Plasma | Pending accreditation | 380 |
| Non-invasive prenatal testing (NIPT) for common microdeletions | 2021NIPTM | Technical, Genotyping and Interpretation | Plasma | Pilot | 380 |
| Non-invasive prenatal testing (NIPT) for fetal sex determination ² | 2021NIPTS | Technical, Genotyping and Interpretation | Plasma | Pending accreditation | 380 |

| | | | | | |
|---|-----------|---|-----------------------------|------------|-----|
| Pregnancy loss (G-banding) | 2021PNPLG | Analytical and Interpretation | Images | Accredited | 380 |
| Pregnancy loss (Molecular methods) | 2021PNPLM | Technical, Genotyping and Interpretation | DNA | Accredited | 380 |
| Prenatal constitutional copy number variation (CNV) detection | 2021PNCNV | Technical, Genotyping and Interpretation | DNA | Accredited | 380 |
| Prenatal karyotyping (Previously AF and CVS) | 2021PNK | Analytical and Interpretation | Images | Accredited | 380 |
| Rapid prenatal testing for common aneuploidies (Previously RA-FISH and MRA) | 2021PNRA | Technical, Analysis / Genotyping & Interpretation | Fixed cell suspension / DNA | Accredited | 380 |

| Molecular Newborn Screening | EQA Code | Analysis | Sample Type | Accreditation status | Fee (£) |
|--|----------|----------------------------|--------------------------|----------------------|---------|
| Molecular testing for cystic fibrosis (CF) | 2021NBSC | Genotyping only (4 rounds) | Neonatal screening cards | Accredited | 850 |
| Molecular testing for Medium-chain acyl-CoA dehydrogenase deficiency (MCADD) | 2021NBSM | Genotyping only (4 rounds) | Neonatal screening cards | Accredited | 850 |
| Molecular testing for Severe Combined Immunodeficiency (SCID) | 2021NBSS | Analytical only (6 rounds) | Neonatal screening cards | Pilot | 820 |

| Postnatal Constitutional | EQA Code | Analysis | Sample Type | Accreditation status | Fee (£) |
|---|--|--|----------------|-----------------------|---------|
| Induced Pluripotent stems (IPS) cells | 2021PIPS | Analytical and Interpretation | Images | Pending | 200 |
| Microdeletion syndromes | 2021PMDEL | Technical, Analytical and Interpretation | Fixed cells | Pilot | 200 |
| Postnatal constitutional copy number variation (CNV) detection ² | 2021PCNV | Technical, Genotyping and Interpretation | DNA | Accredited | 380 |
| Recurrent miscarriage karyotyping (previously Blood-Postnatal) | 2021PRMK | Analytical and Interpretation | Images | Accredited | 380 |
| Sex chromosome disorders karyotyping (previously Blood-postnatal) | 2021PSCK | Analytical and Interpretation | Images | Accredited | 380 |
| Joint Molecular / Cytogenomics | EQA Code | Analysis | Sample Type | Accreditation status | Fee (£) |
| Chromosome breakage syndromes | 2021PCB | Technical, Analytical/ Genotyping & Interpretation | Images and DNA | Pending Accreditation | 380 |
| Disorders of Sexual Development (DSD) | 2021PDSD | Interpretation only | Case scenario | Pilot | 200 |
| Infertility | 2021PINF | Interpretation only | Case scenario | Pilot | 200 |
| Severe Developmental delay | 2021PSDD | Interpretation only | Case scenario | Pilot | 200 |
| Postnatal Constitutional EQA package | Enrol in recurrent miscarriages, sex chromosome disorders karyotyping and infertility and save £160 | | | | |

| Molecular Genetic Disorders | EQA Code | Analysis | Sample Type | Accreditation status | Fee (£) |
|--|-----------|--|-------------|-----------------------|---------|
| Ataxia, including Hereditary Spastic Paraplegia (HSP) | 2021MATAX | Technical, Genotyping and Interpretation | DNA | Accredited | 380 |
| Cardiac disorders | 2021MCARD | Technical, Genotyping and Interpretation | DNA | Accredited | 380 |
| Charcot Marie Tooth disease and related sensory and motor neuropathies | 2021MCMT | Technical, Genotyping and Interpretation | DNA | Accredited | 380 |
| Cystic fibrosis and CFTR-related disorders | 2021MCF | Technical, Genotyping and Interpretation | DNA | Accredited | 380 |
| Epilepsy disorders | 2021MEP | Technical, Genotyping and Interpretation | DNA | Pending accreditation | 380 |
| Eye disorders | 2021MEYE | Technical, Genotyping and Interpretation | DNA | Pending accreditation | 380 |
| Familial Colorectal Cancer and Polyposis | 2021MCRC | Technical, Genotyping and Interpretation | DNA | Accredited | 380 |
| Familial Endocrine tumour predisposition disorders | 2021MENDO | Technical, Genotyping and Interpretation | DNA | Accredited | 380 |
| Familial Hypercholesterolaemia | 2021MFH | Technical, Genotyping and Interpretation | DNA | Accredited | 380 |
| Fragile X syndrome and FMR1-related disorders | 2021MFRA | Technical, Genotyping and Interpretation | DNA | Accredited | 380 |
| Gastrohepatology disorders NEW | 2021MGH | Technical, Genotyping and Interpretation | DNA | Pilot | 100 |
| Hereditary breast and ovarian cancer disorders | 2021MHBOC | Technical, Genotyping and Interpretation | DNA | Accredited | 380 |
| Huntington disease | 2021MHD | Technical, Genotyping and Interpretation | DNA | Accredited | 380 |

| | | | | | |
|--|---|--|--------------------|-----------------------------|----------------|
| Hypotonic Infant | 2021MHI | Technical, Genotyping and Interpretation | DNA | Accredited | 380 |
| Imprinting disorders | 2021MIMP | Technical, Genotyping and Interpretation | DNA | Accredited | 380 |
| Inborn Errors of Metabolism | 2021MIEM | Technical, Genotyping and Interpretation | DNA | Pending accreditation | 380 |
| Linkage analysis | 2021MLINK | Interpretation only | Case scenario | Pending accreditation | 200 |
| Mitochondrial and POLG-related disorders | 2021MMT | Technical, Genotyping and Interpretation | DNA | Accredited | 380 |
| Muscular dystrophies | 2201MMD | Technical, Genotyping and Interpretation | DNA | Accredited | 380 |
| Neurodegenerative disorders | 2021MND | Technical, Genotyping and Interpretation | DNA | Accredited | 380 |
| Neurofibromatosis and rasopathies | 2021MNF | Technical, Genotyping and Interpretation | DNA | Accredited | 380 |
| Osteogenesis Imperfecta NEW | 2021MOI | Technical, Genotyping and Interpretation | DNA | Pilot | 100 |
| Primary Immunodeficiencies NEW | 2021MPI | Technical, Analytical and Interpretation | DNA | Pilot | 100 |
| Renal disorders | 2021MREN | Technical, Genotyping and Interpretation | DNA | Accredited | 380 |
| Respiratory disorders NEW | 2021MRESP | Technical, Genotyping and Interpretation | DNA | Pilot | 100 |
| Skeletal dysplasias, including FGFR2/FGFR3-related disorders | 2021MSKEL | Technical, Genotyping and Interpretation | DNA | Accredited | 380 |
| X-inactivation | 2021MXI | Technical, Analytical and Interpretation | DNA | Accredited | 380 |
| Molecular Genetic Disorder EQA Package Option 1 | Enrol in 15 Molecular Genetics EQAs (excluding pilot EQAs) - Save £250 | | | | |
| Molecular Genetic Disorder EQA Package Option 2 | Enrol in 20 Molecular Genetics EQAs (excluding pilot EQAs) - Save £600 | | | | |
| Pharmacogenetics | EQA Code | Analysis | Sample Type | Accreditation status | Fee (£) |
| Aminoglycoside Induced deafness NEW | 2021MDEAF | Technical, Genotyping and Interpretation | DNA | Pilot | 100 |
| Prediction of 5-Fluorouracil toxicity | 2021MDPYD | Technical, Genotyping and Interpretation | DNA | Pilot | 200 |

| Haematological Neoplasms | EQA Code | Analysis | Sample Type | Accreditation status | Fee (£) |
|--|-----------|--|---------------------------|----------------------|---------|
| Acquired array (CLL and MDS) | 2021HAA | Technical, Analytical and Interpretation | DNA | Accredited | 380 |
| Acute Lymphoblastic Leukaemia (ALL) | 2021HALL | Analytical and Interpretation | Images | Accredited | 380 |
| Chronic Lymphocytic Leukaemia (CLL) IGHV mutation status ¹ | 2021HCLLI | Technical, Genotyping and Interpretation | DNA and lyophilised cells | Pilot | 200 |
| Chronic Lymphocytic Leukaemia (CLL) TP53 analysis ¹ | 2021HCLLT | Technical, Genotyping and Interpretation | DNA and lyophilised cells | Pilot | 200 |
| Chronic Lymphocytic Leukaemia (CLL) (Previously Mature B & T FISH & Mature B & T G-band) | 2021HCLLC | Technical, Analytical and Interpretation | Fixed cells/Images | Accredited | 380 |
| Haematological Technical FISH | 2021HTF | Technical and Analytical | Fixed cells | Pilot | 380 |
| Lymphoma (Previously Mature B & T FISH & Mature B & T G-band) | 2021HLYM | Technical, Analytical and Interpretation | Fixed cells / FFPE/Images | Accredited | 380 |
| Myeloid disorders | 2021HMD | Analytical and Interpretation | Images | Accredited | 380 |
| Myeloma | 2021HMM | Technical, Analytical and Interpretation | Images/ Fixed cells/DNA | Accredited | 380 |



| Molecular Pathology | EQA Code | Analysis | Sample Type | Accreditation status | Fee (£) |
|--|-----------|---|-------------|----------------------|---------|
| Breast cancer (PIK3CA testing) NEW | 2021TBPCP | Genotyping only | FFPE | Pilot | 100 |
| Breast Cancer - Tumour expression profiling NEW | 2021TEP | Genotyping only | FFPE | Pilot | 100 |
| Central Nervous System (CNS) tumours | TCNS | Technical, Genotyping and Interpretation | FFPE | Accredited | 380 |
| Colorectal cancer Option 1 core | 2021TCRC | Technical, Genotyping and Interpretation (two rounds) | FFPE | Accredited | 680 |

| | | | | | |
|---|------------|---|-------------------|-----------------------|-----|
| Colorectal cancer Option 2 mismatch repair (MMR) | 2021TCMSI | Technical, Genotyping and Interpretation (two rounds) | FFPE | Accredited | 810 |
| Colorectal cancer Option 3 Extended MMR | 2021TCMMR | Technical, Genotyping and Interpretation (two rounds) | FFPE | Accredited | 810 |
| Gastrointestinal Stromal Tumours (GIST) | 2021TGT | Genotyping only | FFPE | Accredited | 265 |
| Lung cancer - Option 1 EGFR | 2021TLE | Technical, Genotyping and Interpretation (two rounds) | FFPE | Accredited | 680 |
| Lung cancer - Option 2 core | 2021TLC | Technical, Genotyping and Interpretation (two rounds) | FFPE | Accredited | 680 |
| Lung cancer - Option 3 comprehensive | 2021TLALL | Technical, Genotyping and Interpretation (two rounds) | FFPE | Accredited | 810 |
| Lung cancer - Option 4 fusions | 2021TLF | Technical, Genotyping and Interpretation (two rounds) | FFPE | Accredited | 680 |
| Lung cancer - Circulating free (cf) DNA in lung cancer ² | 2021TCFD | Technical, Genotyping and Interpretation | Artificial plasma | Pending Accreditation | TBC |
| Melanoma | 2021TM | Technical, Genotyping and Interpretation (two rounds) | FFPE | Accredited | 680 |
| Microsatellite Instability (MSI) | 2021TMSI | Technical, Genotyping and Interpretation | FFPE / DNA | Accredited | 265 |
| Molecular Tissue identification | 2021TMT | Technical, Genotyping and Interpretation | FFPE | Accredited | 265 |
| Neuroblastoma | 2021TNB | Technical, Genotyping and Interpretation | Images or DNA | Pilot | 265 |
| Ovarian cancer - BRCA testing in ovarian cancer (germline) ² | 2021TBROVG | Technical, Genotyping and Interpretation | DNA | Accredited | 0 |
| Ovarian cancer - BRCA testing in ovarian cancer (somatic) ² | 2021TBROVS | Technical, Genotyping and Interpretation | FFPE | Accredited | 0 |
| Pan cancer NTRK testing | 2021TNTRK | Technical, Genotyping and Interpretation | FFPE | Pilot | 265 |
| Prostate cancer - HRR testing in prostate cancer ² | 2021THRR | Technical, Genotyping and Interpretation | | Pilot | 100 |
| Renal tumours NEW | 2021TRT | Genotyping only | FFPE | Pilot | 100 |
| Sarcoma | 2021TSA | Technical, Genotyping and Interpretation | FFPE | Accredited | 265 |
| Thyroid cancer NEW | 2021TT | Genotyping only | FFPE/DNA | Pilot | 100 |

| Variant Classification | EQA Code | Analysis | Sample Type | Accreditation status | Fee (£) |
|---|-----------|---|---------------|-----------------------|---------|
| Exome Sequencing Data Interpretation NEW | 2021VEX | Interpretation only | Case scenario | Pilot | 100 |
| ISCN Accuracy NEW | 2021VISCN | Interpretation only | Case scenario | Pilot | 100 |
| Pathogenicity of germline sequence variants (Classification only) | 2021VGC | Interpretation only | Case scenario | Accredited | 200 |
| Pathogenicity of germline sequence variants (Classification & Interpretation) | 2021VGCI | Interpretation only | Case scenario | Accredited | 200 |
| Pathogenicity of somatic sequence variants (Classification only) | 2021VSC | Interpretation only | Case scenario | Pilot | 200 |
| Pathogenicity of germline postnatal copy number variants (CNV) (Classification) | 2021VCNV | Interpretation only | Case scenario | Pilot | 100 |
| Variant validation | 2021VVAL | Analytical, genotyping and interpretation | DNA | Pending Accreditation | 380 |

| Clinical Genetics | EQA Code | Analysis | Sample Type | Accreditation status | Fee (£) |
|--------------------------|----------|--|---------------|-----------------------|---------|
| Cardiovascular disorders | 2021CGC | Interpretation only. Various syndromes involving cardiovascular disorders with a genetic etiology. | Case scenario | Pending Accreditation | 135 |
| Dysmorphology | 2021CGD | Interpretation only. Various syndromes involving dysmorphism(s) with a genetic etiology. | Case scenario | Pending Accreditation | 135 |

| | | | | | |
|---|---|--|---------------|-----------------------|-----|
| Monogenic disorders | 2021CGM | Interpretation only. Various syndromes involving single gene(s) disorders. | Case scenario | Pending Accreditation | 135 |
| Oncogenetic disorders | 2021CGO | Interpretation only. Various cancers with a genetic predisposition or inherited. | Case scenario | Pending Accreditation | 135 |
| Genetic counselling NEW | 2021CGGC | Interpretation only. Pre and Post- test counselling for Cancer, Prenatal Diagnosis, and Genetic disorders/ diseases. | Case scenario | Pilot | 100 |
| Clinical Genetics EQA Package | Enrol in 4 Clinical genetics EQAs - get Genetic Counselling for free | | | | |

| Individual Competency Assessment | | Type of EQA | Number of users | Fee (£) |
|---|--|-----------------------|------------------|-----------------|
|  G-TACT Genetics Training and Competency Tool | | Individual competency | <10 | £500 |
| Online competency assessment modules for individuals working in specific areas of the genetics laboratory (sample reception, variant analysis and report authorisation). The annual fee provides access to all available modules. Continuously available throughout the year. | | | 11 to 20 | £900 |
| | | | 21-30 | £1050 |
| | | | additional 10 | £350 |
| BRCA Variant Classification | | Individual competency | Unlimited | Free |
| Online competency assessment module for classifying the pathogenicity of <i>BRCA1</i> and <i>BRCA2</i> variants. Sponsored by AstraZeneca. Registration open during Summer 2020. | | | | |
| Single Nucleotide Variant (SNV) Classification (trial) | | Individual competency | Unlimited | Free |
| Online competency assessment module for classifying the pathogenicity of 5 SNVs. Registration period will be advertised. | | | | |
| Copy Nucleotide Variant (CNV) Classification (trial) | | Individual competency | Unlimited | Free |
| Online competency assessment module for classifying the pathogenicity of 5 CNVs. Registration period will be advertised. | | | | |
| Somatic Variant Classification (trial) | | Individual competency | Unlimited | Free |
| Online competency assessment module for classifying the pathogenicity of 5 somatic variants. Registration period will be advertised. | | | | |
|  Assessment of tumour content and cellularity of the tissue samples | | Individual competency | Up to 3 | £480 |
| Online tissue assessment module for assessment of cellularity and tumour content of FFPE tissue. Registration period will be advertised. | | | Additional users | £100 per person |

Key

EQA: External quality assessment
 FISH: Fluorescent in situ hybridisation
 FFPE: Formalin fixed paraffin embedded
 TBC: To be confirmed

Notes

¹ Provided in collaboration with UKNEQAS LI
² Provided in collaboration with EMQN
 All EQAs are provided as a single round (distribution) unless otherwise stated